YullEdwinArriagaMD

Oncology • Dallas, TX

Gastrointestinal Cancer, Genitourinary Oncology, Hematologic Oncology, Melanoma

Associate Professor, Internal Medicine, University of Texas Southwestern Medical Center, Southwestern Medical School

Join to view full profile

Dr. Arriaga is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Arriaga's full profile

Already have an account?

Office
5323 Harry Hines Blvd
Dallas, TX 75390
Phone+1 214-645-8600

Education & Training

University of Texas Southwestern Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 1994 - 1997
Cayetano Heredia UniversityClass of 1991

Certifications & Licensure

AZ State Medical License 1997 - Present
NJ State Medical License 2024 - 2025
TX State Medical License 2006 - 2025
PA State Medical License 2023 - 2024
MI State Medical License 1996 - 2000
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012

Clinical Trials

Pioglitazone as Second-Line in Patients With Metastatic Pancreatic Cancer After Treatment With Gemcitabine Start of enrollment: 2009 Mar 02
Terminated
Early Phase 1
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Start of enrollment: 2010 Oct 15
Completed
Phase 2

Publications & Presentations

PubMed

15 citations
Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results.
Adi Diab, Helen Gogas, Shahneen Sandhu, Georgina V Long, Paolo A Ascierto
Journal of Clinical Oncology. 2023-10-20
59 citations
Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery.
Steven M. Lucas, Robert S. Svatek, Guadencio Olgin, Yull Edwin Arriaga, Wareef Kabbani
BJU International. 2008-07-01
42 citations
Artificial intelligence in oncology: Path to implementation
Isaac S. Chua, Michal Gaziel-Yablowitz, Zfania Tom Korach, Kenneth L. Kehl, Nathan A Levitan
Cancer Medicine. 2021-05-07

Journal Articles

Blocking Monocytic Myeloid-Derived Suppressor Cell Function via Anti-DC-HIL/GPNMB Antibody Restores the in Vitro Integrity of T-cells from Cancer Patients
Kevin Courtney, Yull Arriaga, Barbara Haley, John C Mansour, Ponciano D Cruz, David Harker, Farshid Araghizadeh, Clinical Cancer Research

Lectures

Systematic review of gastrointestinal cancer studies of concordance with expert opinion for a clinical decision support system (CDSS).
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/25/2020

Press Mentions

What Is Melanoma?July 8th, 2021

Professional Memberships

American Society of Clinical Oncology - ASCO
Member